Interferon Alpha-2a Treatment in Patients with Hepatitis C and Bleeding Disorders

Abstract

In 1943, Beeson observed a connection between the transfusion of blood products and the emergence of hepatitis [1]. Jaundice developed in seven patients 1–4 months after the administration of whole blood or plasma. Further reports on the development of hepatitis in hemophilia patients were published in the mid-1970s [2, 3, 4]. Today, it is generally accepted that the hepatitis C virus causes the majority of cases of post-transfusion hepatitis in the Western world. It is responsible for most chronic liver disorders observed in hemophilia patients treated with clotting factor concentrates. The hepatitis C infection can be associated with replacement therapy involving clotting factor concentrates applied in the early 1970s [2, 5, 6].